xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

602

INTERNATIONAL CONSENSUS ON OLFACTION

TABLE IX-32 Use of zinc to treat OD Study Year

LOE Study design

Study groups

Clinical end point Conclusions

Most common

Zinc sulphate did not show significant improvement in both subjective symptom scores and objective scores, including with SS The recovery rates of OF in groups 1 and 2 were significantly higher than the recovery rate in group 4 (group 3 also showed recovery, andwasnot significantly different when compared with groups 1 and 2) Improvement could be attributable to the use of prednisolone rather thanzinc significant difference in the 2 study groups in loss or distortion of smell No statistically worsening in loss of smell over time in the zinc study group The use of zinc sulphate did not produce any significant measurable improvement in olfaction A trend towards nonsignificant

Harless

2016

1

Systematic review Pharmacological treatments for the management of PVOD 8 articles were included, yielding 563 patients

et al 458

assessment: SS-TDI

Jiang

2015

2

Prospective,

Patient cohort:

6-month trial PEA threshold testing

et al 1350

randomized

posttraumatic anosmia

(N = 145) Zinc gluconate and prednisolone (n = 39) Zinc gluconate (n = 35) Prednisolone (n = 34) No medication (n = 37) Postchemotherapy patient cohort (n = 58) Zinc sulphate 220 mg orally twice daily (n = 20) Placebo (n = 21) mg/day (n = 51) Zinc sulphate 400 mg/day (n = 56) Patient cohort: sensorineural olfactory loss (postviral, (N = 426) Zinc sulphate 300 mg daily (n = 25) Zinc sulphate plus topical corticosteroids and oral vitamin B (n = 142) posttraumatic, or unknown) Patient cohort: nonconductive olfactory disorders (n = 77) Caroverine 120

Lyckholm et al 452

3-month follow-up Patient questionnaire using 1 to 100 scale

2012

2

Double-blinded,

placebo-controlled, randomized clinical

Quint

2002

3

Prospective clinical

4-week study SS test (butanol) SS-ID (16 odors)

et al 1567

50% of patients with PVOD reported subjective mild to significant

Follow-up time

Aiba

1998

3

Retrospective, nonblinded,

et al 450

unclear but listed as at least 1 month Subjective symptom improvement based on 7 point scale

noncontrolled, parallel group clinical

improvement, but no statistical difference between the groups pretreatment serum zinc levels

No association with

Adverse effects not discussed

Topical

corticosteroids and vitamin B (n = 259)

(Continues)